Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,311,679 | 1,250,108 | 1,213,816 | 1,048,803 | 942,842 |
| Marketable Securities | 248,930 | 227,731 | 218,309 | 223,532 | 194,864 |
| Receivables | 908,214 | 790,266 | 855,855 | 739,177 | 660,535 |
| Inventories | 1,298,883 | 1,382,173 | 1,340,169 | 1,274,848 | 1,232,653 |
| Other current assets | 185,784 | 204,265 | 177,183 | 181,545 | 201,533 |
| TOTAL | $3,953,490 | $3,854,543 | $3,805,332 | $3,467,905 | $3,232,427 |
| Non-Current Assets | |||||
| PPE Net | 952,508 | 1,038,187 | 1,030,385 | 1,032,613 | 1,043,041 |
| Investments And Advances | 492,242 | 512,937 | 508,592 | 506,724 | 521,238 |
| Intangibles | 410,036 | 429,311 | 435,819 | 443,545 | 451,477 |
| Other Non-Current Assets | 1,785,746 | 1,779,890 | 1,676,213 | 1,696,220 | 1,740,757 |
| TOTAL | $3,640,532 | $3,760,325 | $3,651,009 | $3,679,102 | $3,756,513 |
| Total Assets | $7,594,022 | $7,614,868 | $7,456,341 | $7,147,007 | $6,988,940 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 759,031 | 798,438 | 684,247 | 628,213 | 606,988 |
| TOTAL | $759,031 | $798,438 | $684,247 | $628,213 | $606,988 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 747,992 | 759,719 | 744,981 | 725,335 | 723,962 |
| TOTAL | $747,992 | $759,719 | $744,981 | $725,335 | $723,962 |
| Total Liabilities | $1,507,023 | $1,558,157 | $1,429,228 | $1,353,548 | $1,330,950 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 192,323 | 192,114 | 192,015 | 191,776 | 190,777 |
| Common Shares | 192 | 192 | 192 | 192 | 191 |
| Retained earnings | 154,206 | 200,779 | 231,523 | -9,009 | -194,695 |
| Other shareholders' equity | -23,981 | -45,228 | -56,239 | 7,974 | 50,426 |
| TOTAL | $6,086,999 | $6,056,711 | $6,027,113 | $5,793,459 | $5,657,990 |
| Total Liabilities And Equity | $7,594,022 | $7,614,868 | $7,456,341 | $7,147,007 | $6,988,940 |